The Revised PrEP Guidelines

TargetHIV

The December 2021 update of CDC PrEP guidelines contains a series of recommendations for providers to broaden their discussions and prescribing of the HIV preventive regimen.

There are no revisions regarding the populations recommended for PrEP and no changes regarding dosing and HIV/STI testing frequency. Descovy has been added as an option while new language covers prescribing the injectable cabotegravir (CAB), pending FDA approval.

The guidelines, Preexposure Prophylaxis for the Prevention of HIV Infection in the United States (2021 Update), includes two documents: Clinical Practice Guideline and Clinical Providers Supplement. 

Read a summary of revisions in the December 8, 2021 Dear Colleague letter from CDC's Division of HIV/AIDS Prevention.

Paying for PrEP

Most insurance plans and Medicaid pay for PrEP, at no cost to patients. This is largely because of a 2019 recommendation by the U.S. Preventive Services Task Force (USPSTF) endorsing PrEP coverage, which in turn triggered an Affordable Care Act provision mandating health insurance plans to provide no cost coverage of USPSTF-recommended preventive services.

Learn about Paying for PrEP.

 

Remote video URL

We'd like your feedback

Was this page helpful?
I found this page helpful because the content on the page:
Check all that apply
I did not find this page helpful because the content on the page:
Check all that apply
Please include an email address if you would like a response
Please include an email address if you would like a response